Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation ( ADPT ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - VP, CFO & Principal Accounting Officer Susan Bobulsky - Chief Commercial Officer of MRD Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Subbu Nambi Andrew Brackmann - William Blair & Company L.L.C., Research Division Sebastian Sandler - JPMorgan Chase & Co, Research Division William Bonello David Westenberg - Piper Sandler & Co., Research Division Daniel Brennan Presentation Operator Good day, and thank you for standing by.
Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies Corporation (ADPT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Chad Robins - Co-Founder, CEO & Chairman Kyle Piskel - VP, CFO & Principal Accounting Officer Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics team here at Morgan Stanley.
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Aristotle Focus Growth Q2 Highlights: Top Performers, Surprises And Strategic Shifts
Adaptive Biotechnologies and Netflix were top contributors, driven by strong earnings, momentum in core businesses, and positive outlooks. UnitedHealth Group and Visa detracted from performance due to earnings weakness, guidance cuts, and potential disruption from stablecoins. We initiated a position in HubSpot for its strong SMB positioning, AI-driven growth, and scalable financials, while exiting Expedia due to recession risks.
Adaptive Biotechnologies Corporation (ADPT) Q2 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Chad M. Robins - Co-Founder, CEO & Chairman Karina Calzadilla - Vice President of Investor Relations Kyle Piskel - VP, CFO & Principal Accounting Officer Susan Bobulsky - Chief Commercial Officer of MRD Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
